ViroXis Corporation Signs Exclusive License Agreement With Global Pharmaceutical Company To Commercialize An OTC Dermatology Product
2/26/2014 8:57:08 AM
SAN ANTONIO--(BUSINESS WIRE)--ViroXis Corporation is pleased to report the execution of an exclusive license agreement with a global pharmaceutical company for the marketing of an over-the-counter (OTC) sandalwood oil-containing product. The long-term agreement includes a licensing fee, milestone payments and royalties based on product sales. The pharmaceutical partner is exclusively dedicated to dermatology and is a world leader in dermatology products with an extensive product portfolio available in 80 countries. The license agreement anticipates worldwide commercialization of the OTC product, with an initial product launch in the U.S. anticipated in early 2015.
Help employers find you! Check out all the jobs and post your resume.
comments powered by